Comparison of the number of image acquisitions and procedural time required for transarterial chemoembolization of hepatocellular carcinoma with and without tumor-feeder detection software.
Two randomized trials have shown that transarterial chemoembolization (TACE) confers significant survival benefits [1, 2]. It has subsequently been accepted as a standard locoregional therapy for managing unresectable hepatocellular carcinoma (HCC). Detection of tumor feeders using intraprocedural imaging is indispensable for the technical success of this procedure. However, sequential angiographic acquisitions are usually necessary to accurately determine the feeder vessels in manual assessments using two-dimensional (2D) angiography. Additional angiographic runs at different angles are often required in patients with highly complex hepatic arterial vasculature. Such efforts are time-consuming and increase radiation exposure and contrast material use.
A software program specifically designed to assist in planning selective liver tumor embolization (FlightPlan for Liver, GE Healthcare, Waukesha, WI, USA) was recently developed to detect and visualize potential tumor feeders from three-dimensional (3D) C-arm computed tomography (CT) data . When catheter entry and a target tumor are chosen on the multiplanar reformatted (MPR) C-arm CT images, the software automatically predicts tumor feeders by showing a color-coded image on the workstation screen. With only a single acquisition of a nonselective C-arm CT during contrast injection from the proximal hepatic artery, the software then determines each intrahepatic tumor feeder supplying every liver tumor. Therefore, software-assisted TACE is theoretically expected to reduce the number of total image acquisitions and overall procedural time by sparing unnecessary catheterizations.
In this study, we compared the number of image acquisitions and overall procedural times required for TACE with and without assistance of the automated feeder-vessel detection software in cases of HCC.
2. Materials and Methods
2.1. Patients. We retrospectively reviewed the records of patients with HCC who came to Nissay Hospital and underwent lipiodol-based TACE using a C-arm cone-beam angiographic system between January 2010 and February 2013. Patients with diffuse and infiltrative HCC or an extrahepatic supply to the tumor were excluded from this study. The study group comprised 134 patients. Fifty patients (September 2011--February 2013) were treated with the assistance of the tumor-feeder detection software, whereas 84 patients (January 2010-August 2011) received treatment without software assistance.
This study was conducted in accordance with the guidelines of our Institutional Review Board. Before TACE, each patient provided written, informed consent for the use of the software.
2.2. TACE without Software Assistance. Angiographic procedures were performed by one of two board-certified interventional radiologists who used a flat panel detector C-arm angiographic system (Innova 3100, GE Healthcare). First, a 4-Fr catheter was placed in the celiac artery via the femoral artery. A right or left hepatic artery angiogram was subsequently obtained through a coaxially inserted microcatheter. If the hepatic arteries overlapped on the frontal angiogram, an additional angiogram in a different angle was further obtained. If the tumor stain was obscure on the angiogram, an additional C-arm CT image was acquired during contrast injection from the same hepatic artery.
After the radiologists confirmed the target tumor, 1.7-to 2.7-Fr microcatheters were advanced into the suspected tumor feeders. Angiograms and C-arm CT images were obtained from the suspected feeder artery to confirm whether the target tumor was located within the treatment area. If the investigated feeder artery was not the true feeder vessel, the microcatheter was replaced into the second most probable arterial branch. When multiple tumors existed, the same procedure for each target tumor was attempted. After confirming the true feeder artery, the hepatic areas containing the target tumors were infused with an appropriate dose of chemotherapeutic agents mixed with lipiodol (Lipiodol Ultrafluid; Terumo, Tokyo, Japan) and embolized with gelatin particles (Gelpart; Nippon Kayaku, Tokyo, Japan) until the tumor vessels were completely filled. Postprocedural C-arm CT images were obtained to ensure that no viable tumors or additional tumor feeders remained.
2.3. TACE with Software Assistance. After performing celiac angiography using a 4-Fr catheter, a microcatheter (2.0-2.7 Fr) was inserted coaxially into the common or proper hepatic artery. Nonselective C-arm CT images from the artery were subsequently obtained. C-arm CT data sets were automatically transferred to the external workstation (Advantage Workstation 5.0; GE Healthcare) in which a 3D hepatic arterial tree was constructed for further vascular mapping. By using the imaging data of nonselective C-arm CT, software analysis was attempted to determine tumor feeders for all targets. In patients with many tumor burdens (generally 5 or more lesions in the treatment area), the tumor feeder was extracted using the software only for the largest tumor.
After the software indicated the tumor feeder, 1.7-Fr to 2.7-Fr microcatheters were advanced into the suggested tumor feeders, regardless of whether the vessel was a feeder. A C-arm CT image of the probable tumor feeder was acquired during the contrast injection to confirm whether the vessel supplied the target tumor. The radiologists confirmed the feeder vessel when the target tumor was enhanced on the C-arm CT by referencing the pretreatment CT or magnetic resonance images. The hepatic areas containing target tumors were subsequently chemoembolized, as described previously. If the suggested vessels did not supply the target, the second most probable feeder was determined manually by using the previously obtained angiograms and C-arm CT images. Postprocedural C-arm CT images were then obtained to ensure that no viable tumors or additional tumor feeders were missed.
2.4. C-Arm Computed Tomography. C-arm CT image was acquired with the following parameters: total scanning angle, 200[degrees]; rotation speed, 20[degrees]/s or 40[degrees]/s; acquisition time, 5 s; matrix size, 1500 x 1500; isotropic voxel size, 0.2 mm; and effective field of view, 18 [cm.sup.2]. Vascular images for software analysis were obtained by injecting 10-15 mL of iopamidol at a flow rate of 1.0-1.5 mL/s into the common or proper hepatic artery, depending on the perfusion area. Contrast material flowed for 10 s; therefore, the total volume injected depended on the flow rate. Data acquisition started 7-8 s after the intra-arterial injection of contrast material. Volume data sets were transferred to an external workstation (Advantage Workstation 4.2 or 5.0; GE Healthcare) in which the images were reconstructed in multiple planes. The size and number of tumors were determined from the C-arm CT images acquired during each TACE session.
2.5. Software Analysis. Detection of tumor feeders utilizing the software was performed during the angiographic session by a single radiology technologist who had more than 30 years' experience in angiographic image acquisition. All image analyses related to tumor-feeder detection were performed on the same commercial workstation (Advantage Workstation 5.0; GE Healthcare). After acquiring the C-arm CT data, the technologist chose the catheter entry site on the MPR images. By using the software's extraction function, the arterial vasculature and all the tumors were displayed as a circumscribed image on the 2D MPR in approximately 15 s. The technologist subsequently placed a circular region-of-interest (ROI) on the target tumor in the 2D MPR images to cover the entire tumor. Then, with the extraction function, the software analyzed the most probable tumor feeders that connected the selected catheter entry to the target region and displayed color-coded images in approximately 30 s. The total processing time required--from the time the C-arm CT image was available to the time when the technologist completed the tumor-feeder detection with the software--was approximately 2 min.
2.6. Treatment Evaluation. The therapeutic efficacy of TACE was evaluated on the basis of the change in the maximum diameter of the viable portion of the target lesions, as observed on triphasic contrast-enhanced CT images acquired 1-3 months after therapy. Recurrence was confirmed by evidence of an abnormal early enhancement in arterial phase images from contrast-enhanced CT. The response was evaluated according to the modified Response Evaluation Criteria in Solid Tumors . The response categories were complete response (CR; disappearance of any intratumoral arterial enhancement), partial response (PR; at least a 30% decrease in the sum of the diameters of viable lesions), stable disease (SD; any cases that did not qualify for the other 3 categories), and progressive disease (PD; at least a 20% increase in the sum of the diameters of viable lesions). Objective response (OR) was defined as the sum of the cases that were categorized as CR and PR. The areas of lesions in which lipiodol uptake was observed were considered as necrotic tissue.
2.7. Data and Statistical Analyses. One interventional radiologist who participated in all angiographic procedures performed the data analysis. The number of image acquisitions and the overall procedural time were assessed, based on the patient record chart and on data from the picture archiving and communication system (PACS). The images included the first celiac artery angiogram to the last posttreatment C-arm CT. The overall procedural time of a single TACE session was the time between the insertion and the removal of a 4-Fr sheath. The Mann-Whitney U test or Fisher's exact test was used to compare the parameters of both study groups.
All tests were two-sided. Factors were considered statistically significant with a P < 0.05.
3.1. TACE. Table 1 summarizes the baseline characteristics of the patients who underwent TACE with and without software assistance. There were no significant differences between the study groups in any of the factors investigated. We initially performed TACE for 84 patients in 134 hepatic areas without software assistance and for 50 patients in 87 hepatic areas using the software. Figure 1 shows a representative case treated with software-assisted TACE.
3.2. The Number of Image Acquisitions. Table 2 lists the mean number of angiographies and C-arm CT image acquisitions in a single session of TACE. The number of angiography acquisitions per session reduced significantly with the assistance of software, irrespective of the patient's tumor multiplicity. The overall angiography acquisition reduced from 6.6 times to 4.6 times with the assistance of software (P < 0.001). The number of C-arm CT acquisitions per session did not differ between the groups. Total image acquisition significantly decreased from 9.7 times to 7.1 times with the use of software analysis in TACE for a single lesion (P = 0.001). For multiple lesions, total image acquisition reduced from 11.0 times to 9.6 times with the software; however, the difference did not reach a statistical significance. Overall image acquisitions per session significantly reduced from 10.4 times to 8.7 times with the software (P = 0.004).
3.3. Procedural Time. Table 3 shows the mean procedural
time needed for single-session TACE with and without software assistance. The overall procedural time significantly lowers with software assistance than without it (103 min versus 116 min, P = 0.021). The procedural time was significantly lower in TACE for a single lesion (88 min versus 109 min, P = 0.013), but the difference was not significant for multiple lesions.
3.4. Treatment Response. The therapeutic efficacies of the study groups are listed in Table 4. There were no significant differences in the overall treatment response between the 2 groups (P = 0.728). A CR was obtained in 34 (68%) patients and 53 (63%) patients who received TACE with and without software assistance, respectively. An OR was obtained in 39 (78%) patients and 68 (80%) patients who received TACE
with and without software assistance, respectively. No significant differences were found in the CR (P = 0.565) or OR (P = 0.680) rates between the 2 groups.
The reported sensitivity in detecting tumor feeders using the software varies from 80% to 93% [3,5-7]. All previous studies suggested that the software more accurately enables the identification of tumor feeders than that achieved with a manual assessment using angiography. Furthermore, the processing time required for detecting tumor feeders with the software ranged from 135 s to 142 s [3, 6]. The time necessary for a software analysis was significantly shorter than the time for a standard 2D angiography 5, 6]. However, whether the software actually influences the number of image acquisitions and overall procedural time has not yet been investigated.
Our current study demonstrated that the feeder-vessel detection software reduced both the total number of image acquisitions and the overall procedural time in TACE of HCC without influencing the therapeutic efficacy. The software can identify a tumor feeder, even from a nonselective C-arm CT arteriography and thus facilitates direct placement of a micro-catheter into the feeder vessels without the need for sequential angiography. With this particular capability, the software can potentially reduce radiation exposure and contrast material use, though we did not evaluate these factors in this study.
It is sometimes difficult to recognize a target location with angiography alone, if the target tumor is small or less enhanced [8-11]. However, these tumor factors do not interfere with the software analysis because C-arm CT has an adequate sensitivity for detecting small and less enhanced HCC lesions [10-13]. Using software for these lesions can avoid sequential catheterizations into all possible arterial branches toward the tumor area and spare a patient from unnecessary additional imaging acquisitions.
Angiographic assessment of multiple tumor feeders supplying a single lesion usually requires multiple image acquisitions for each feeder. However, the software can determine multiple tumor feeders simultaneously in a single process from the nonselective C-arm CT data. Even in patients with multiple tumors, each tumor feeder can be determined from a single acquisition of a nonselective C-arm CT image during contrast injection from the common or proper hepatic artery.
Multiple software processes are necessary to detect each tumor feeder supplying a tumor. A radiology technologist can alternatively participate in the software analysis and thus spare the operating angiographer from procedural interruption. The software also helps to determine the optimal working angle. If it is difficult to ascertain the origin or vasculature of tumor feeders because of overlapping on the frontal image, an optimal 3D roadmap in association with color-coded feeder vessels at any angle can be optimized for better viewing without obtaining additional oblique angiography. With this capability, the software can potentially reduce radiation exposure and contrast material use.
However, the software has several fundamental limitations. It was designed for selective transcatheter therapy; therefore, its benefit is limited in lobar or whole-liver embolization in patients with numerous or infiltrative tumor burdens. Our current data showed that the total image acquisition and the overall procedural time were indeed slightly reduced in patients with multiple lesions; however, the difference did not reach a statistical significance, even with the use of software. Furthermore, the input imaging data originates from the C-arm CT data obtained from the common or proper hepatic artery; therefore, arteries originating from a more proximal contrast injection site cannot be depicted. Therefore, the software would not recognize tumor feeders arising from the extrahepatic arteries, such as the left gastric artery or the phrenic artery. An angiographer can recognize an extrahepatic supply to a certain hepatic area by detecting the absence of perfusion on a nonselective C-arm CT image. However, manual survey for extrahepatic feeder vessels would be necessary. Furthermore, approximately 10% of the feeder arteries indicated by software analysis are false feeders [3,5-7]. If an investigated vessel is identified as false, the subsequent placement of a microcatheter into other probable feeder vessels should be performed without the guidance of software analysis.
This study had a few limitations. First, it was a retrospective comparative analysis. The results of this study may include selection and information biases. Second, despite the decreased number of total image acquisitions with the software, the radiation exposure to the patients or the operators was not evaluated in this study. Third, we were unable to assess the total amount of contrast material used in a single-session TACE because we had not recorded the dose of the contrast material used. Fourth, we did not use 3D images of the C-arm CT for assessing tumor feeders in software-free TACE. The use of such imaging in association with angiography may have improved the detection of tumor feeders in those patients who were analyzed without using software. Fifth, not all tumor feeders were assessed with software analysis, especially those patients who had lobar TACE for multiple tumors. This may have influenced the number of image acquisitions and the procedural time. Sixth, we excluded the study patients who had infiltrative tumors or tumors with an extrahepatic supply. This exclusion made the study patient group somewhat unusual for a daily clinical setting.
In conclusion, the use of a C-arm angiographic system equipped with automated feeder-vessel detection software in TACE of HCC helped to reduce the number of total image acquisitions and the overall procedural time while maintaining a comparable treatment efficacy, as compared to that of TACE without software assistance.
Conflict of Interests
The authors have no conflict of interests to declare.
 C.-M. Lo, H. Ngan, W.-K. Tso et al., "Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectable hepatocellular carcinoma," Hepatology, vol. 35, no. 5, pp. 1164-1171, 2002.
 J. M. Llovet, M. I. Real, X. Montana et al., "Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial," Lancet, vol. 359, no. 9319, pp. 1734-1739, 2002.
 E. Pichon, G. Bekes, F. Deschamps, and S. B. Solomon, "Development and preliminary evaluation of software for planning selective liver embolizations from three-dimensional rotational fluoroscopy imaging," International Journal of Computer Assisted Radiology and Surgery, vol. 3, no. 5, pp. 405-412, 2008.
 R. Lencioni and J. M. Llovet, "Modified recist (mRECIST) assessment for hepatocellular carcinoma," Seminars in Liver Disease, vol. 30, no. 1, pp. 52-60, 2010.
 S. B. Solomon, R. Thornton, F. Deschamps et al., "A treatment planning system for transcatheter hepatic therapies: pilot study," Journal of Interventional Oncology, vol. 1, no. 1, pp. 12-18, 2008.
 F. Deschamps, S. B. Solomon, R. H. Thornton et al., "Computed analysis of three-dimensional cone-beam computed tomography angiography for determination of tumor-feeding vessels during chemoembolization of liver tumor: a pilot study," Cardio Vascular and Interventional Radiology, vol. 33, no. 6, pp. 1235-1242, 2010.
 J. Iwazawa, S. Ohue, N. Hashimoto, O. Muramoto, and T. Mitani, "Clinical utility and limitations of tumor-feeder detection software for liver cancer embolization," European Journal of Radiology, 2013.
 S. Hirota, N. Nakao, S. Yamamoto et al., "Cone-beam CT with flat-panel-detector digital angiography system: early experience in abdominal interventional procedures," Cardio Vascular and Interventional Radiology, vol. 29, no. 6, pp. 1034-1038, 2006.
 S. Kakeda, Y. Korogi, Y. Hatakeyama et al., "The usefulness of three-dimensional angiography with a flat panel detector of direct conversion type in a transcatheter arterial chemoembolization procedure for hepatocellular carcinoma: initial experience," CardioVascular and Interventional Radiology, vol. 31, no. 2, pp. 281-288, 2008.
 J. Iwazawa, S. Ohue, T. Mitani et al., "Identifying feeding arteries during TACE of hepatic tumors: comparison of C-Arm CT and digital subtraction angiography," American Journal of Roentgenology, vol. 192, no. 4, pp. 1057-1063, 2009.
 S. Miyayama, M. Yamashiro, M. Okuda et al., "Usefulness of cone-beam computed tomography during ultraselective transcatheter arterial chemoembolization for small hepatocellular carcinomas that cannot be demonstrated on angiography," CardioVascular and Interventional Radiology, vol. 32, no. 2, pp. 255-264, 2009.
 J. Iwazawa, S. Ohue, N. Hashimoto, H. Abe, M. Hamuro, and T. Mitani, "Detection of hepatocellular carcinoma: comparison of angiographic C-arm CT and MDCT," American Journal of Roentgenology, vol. 195, no. 4, pp. 882-887, 2010.
 H. Higashihara, K. Osuga, H. Onishi et al., "Diagnostic accuracy of C-arm CT during selective transcatheter angiography for hepatocellular carcinoma: comparison with intravenous contrast-enhanced, biphasic, dynamic MDCT," European Radiology, vol. 22, no. 4, pp. 879-872, 2012.
Jin Iwazawa, (1) Shoichi Ohue, (2) Naoko Hashimoto, (1) and Takashi Mitani (1)
(1) Department of Radiology, Nissay Hospital, 6-3-8 Itachibori, Nishi-ku, Osaka 550-0012, Japan
(2) Department of Radiology, Komatsu Hospital, 11-6 Kawakatsucho, Neyagawa 572-8567, Japan
Correspondence should be addressed to Jin Iwazawa; firstname.lastname@example.org
Received 17 April 2013; Revised 29 June 2013; Accepted 1 July 2013
Academic Editor: Sotirios Bisdas
Table 1: Baseline patient and tumor characteristics. TACE P With Without software software Gender (female/male) 21/29 29/55 0.390 Age (years)* 73 (37-90) 71 (35-89) 0.079 HBs antigen 5/45 15/69 0.220 (positive/negative) HCV antibody 38/12 60/24 0.567 (positive/negative) Child-Pugh class (A/B) 42/8 60/24 0.100 TNM stage (I/II/III) 12/27/11 24/44/16 0.537 Serum AFP level (ng/mL) * 609 (3-12424) 173 (3-3557) 0.191 Previous treatment 13/37 23/61 0.864 (primary/recurrence) Number of tumors 19/10/6/7/8 42/12/10/8/12 0.258 (1/2/3/4/5 or greater) Maximum tumor size (mm) * 21 (9-47) 21 (8-61) 0.623 Number of treatment areas in 1.7 (1-4) 1.6 (1-4) 0.329 a single session * Treatment area 20/47/11/9 21/72/22/19 .111 (distal/subsegment/ segment/lobe) *Data are expressed as the mean (range). TACE: transarterial chemoembolization. HB: hepatitis B; HCV: hepatitis C virus; AFP: [alpha]-fetoprotein. Table 2: Number of image acquisitions required for a single session of chemoembolization. Number of image acquisition Imaging Tumor TACE with multiplicity software (n = 50) Angiography Single (n = 61) 3.7 [+ or -] 1.0 (2-6) Multiple (n = 73) 5.2 [+ or -] 1.9 (2-10) Overall 4.6 [+ or -] 1.7 (2-10) C-arm CT Single (n = 61) 3.4 [+ or -] 1.3 (2-7) Multiple (n = 73) 4.4 [+ or -] 1.4 (2-7) Overall 4.1 [+ or -] 1.4 (2-7) Total Single (n = 61) 7.1 [+ or -] 1.8 (5-12) Multiple (n = 73) 9.6 [+ or -] 2.7 (5-16) Overall 8.7 [+ or -] 2.7 (5-16) Imaging Tumor TACE without multiplicity software (n = 84) Angiography Single (n = 61) 6.3 [+ or -] 1.7 (3-10) Multiple (n = 73) 7.0 [+ or -] 2.4 (4-14) Overall 6.6 [+ or -] 2.1 (3-14) C-arm CT Single (n = 61) 3.4 [+ or -] 1.5 (2-8) Multiple (n = 73) 4.0 [+ or -] 1.2 (2-7) Overall 3.8 [+ or -] 1.4 (2-8) Total Single (n = 61) 9.7 [+ or -] 3.0 (5-17) Multiple (n = 73) 11.0 [+ or -] 3.2 (6-20) Overall 10.4 [+ or -] 3.2 (5-20) Imaging Tumor P multiplicity Angiography Single (n = 61) <0.001 Multiple (n = 73) 0.001 Overall <0.001 C-arm CT Single (n = 61) 0.884 Multiple (n = 73) 0.215 Overall 0.228 Total Single (n = 61) 0.001 Multiple (n = 73) 0.105 Overall 0.004 Data are expressed as mean [+ or -]standard deviation (range). TACE: transarterial chemoembolization. C-arm CT: C-arm computed tomography. Table 3: Procedural time required for a single chemoembolization. Procedural time (min) Tumor multiplicity TACE with software TACE without software (n = 50) (n = 84) Single (n = 61) 88 [+ or -]22 (44-132) 109 [+ or -]29 (58-187) Multiple (n = 73) 112 [+ or -]35 (50-178) 123 [+ or -]32 (67-228) Overall 103 [+ or -]33 (44-178) 116 [+ or -]31 (58-228) P Single (n = 61) 0.013 Multiple (n = 73) 0.219 Overall 0.021 Data are expressed as mean [+ or -]standard deviation (range). TACE: transarterial chemoembolization. Table 4: Therapeutic efficacy of chemoembolization of hepatocellular carcinoma. TACE with software TACE without software P (n = 50) (n = 84) CR 34 53 PR 5 15 0.728 SD 6 8 PD 5 8 CR rate (%) 68 63 0.565 OR rate (%) 78 80 0.680 The response was evaluated according to the modified Response Evaluation Criteria in Solid Tumors . CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; OR: objective response; TACE: transarterial chemoembolization.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Clinical Study|
|Author:||Iwazawa, Jin; Ohue, Shoichi; Hashimoto, Naoko; Mitani, Takashi|
|Publication:||Radiology Research and Practice|
|Date:||Jan 1, 2013|
|Previous Article:||The features of extrahepatic collateral arteries related to hepatic artery occlusion and benefits in the transarterial management of liver tumors.|
|Next Article:||Geriatric chest imaging: when and how to image the elderly lung, age-related changes, and common pathologies.|